Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart induction and maintenance study in moderately to severely active ulcerative colitis
NL-OMON61226Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Afimkibart with Placebo (2 arms). Primary endpoints: Clinical remission at Week 12 and Clinical remission at Week 52. Started Jan 2025; status: completed.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON61226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61226.